DGAP-Adhoc: Geratherm Medical AG: Geratherm Medical AG announces preliminary figures for financial year 2021
DGAP-Ad-hoc: Geratherm Medical AG / Key word(s): Preliminary Results
Geratherm Medical AG: Geratherm Medical AG announces preliminary figures for financial year 2021
07-Apr-2022 / 16:21 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Publication of insider information in accordance with Article 17 MAR,
transmitted by DGAP - a service of EQS-Group AG
Geratherm Medical AG announces preliminary figures for financial year 2021:
- Revenues EUR 23.9 million (2020: EUR 27.5 Million)
- EBITDA 2,304 kEUR (2020: 4,347 kEUR)
- EBITDA-Margin 9.6% (2020: 15.8%)
- Operating profit (EBIT) 590 kEUR (without depreciation of medical heating blankets for clinical surgery: 1,517 kEUR) (2020: 3,097 kEUR)
- result from ordinary operations 308 kEUR (2020: 2,719 kEUR)
- Earnings per share 2 cents (2020: 41 cents)
- Equity ratio 54.0% (2020: 55.4%)
- Cash and securities EUR 6.5 million (2020: EUR 10.3 million)
- Proposed dividend: 12 cents per share (2020: 40 cents per share)
- Ongoing good international demand for Geratherm medical products
Geratal, April 7, 2022: Geratherm Medical AG (ISIN: DE0005495626) had a stable sales trend in 2021 after the record year 2020. The result was burdened by the one-off expenses of the discontinuation of the medical heating blankets for clinical surgery and further certification expenses.
Geratherm Respiratory and apoplex medical had a good development in 2021. Sales split of the divisions Healthcare Diagnostic EUR 13.9 million, -24.3%; Respiratory EUR 5.6 million, +15.6%; Medical warming systems EUR 2.0 million, -18.5%; Cardio/Stroke 2.5 million EUR, +34.0%.
The detailed Annual Report 2021 will be published on April 26, 2022.
Geratherm Medical AG
Firmensitz: Fahrenheitstraße 1, 99331 Geratal
Registergericht: Amtsgericht Jena, HRB 111272
Vorstand: Dipl.-Kfm. Christian Frick
Aufsichtsratsvorsitzender: Dr. Gert Frank
Tel. 036205/98 0; Fax: 036205/98 115
E-Mail: [email protected] www.geratherm.com
Short company profil:
Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MRI Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.
Contact:
C. Frick
07-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Geratherm Medical AG |
|
Fahrenheitstraße 1 |
|
99331 Geratal |
|
Germany |
Phone: |
+49 (0)36205 98-0 |
Fax: |
+49 (0)36205 98-1 15 |
E-mail: |
[email protected] |
Internet: |
www.geratherm.com |
ISIN: |
DE0005495626 |
WKN: |
549562 |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1323249 |
|
End of Announcement |
DGAP News Service |
1323249 07-Apr-2022 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
21,03 |
21,52 |
19,85 |
27,47 |
23,94 |
25,85 |
20,96 |
EBITDA1,2 |
1,77 |
2,80 |
2,35 |
4,35 |
2,31 |
3,55 |
4,27 |
EBITDA-Marge3 |
8,42 |
13,01 |
11,84 |
15,84 |
9,65 |
13,73 |
|
EBIT1,4 |
0,63 |
1,99 |
1,05 |
3,04 |
0,59 |
2,07 |
2,55 |
EBIT-Marge5 |
3,00 |
9,25 |
5,29 |
11,07 |
2,46 |
8,01 |
12,17 |
Jahresüberschuss1 |
0,22 |
0,83 |
0,29 |
1,90 |
0,33 |
1,08 |
1,67 |
Netto-Marge6 |
1,05 |
3,86 |
1,46 |
6,92 |
1,38 |
4,18 |
7,97 |
Cashflow1,7 |
2,47 |
1,35 |
1,54 |
3,92 |
0,92 |
2,79 |
1,47 |
Ergebnis je Aktie8 |
0,14 |
0,23 |
0,11 |
0,41 |
0,02 |
0,19 |
0,21 |
Dividende8 |
0,47 |
0,40 |
0,25 |
0,40 |
0,12 |
0,15 |
0,50 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. ![](/wp-content/uploads/assets/icon/pdf_24x24.png)
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Baker Tilly
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Geratherm Medical |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
549562 |
3,840 |
Verkaufen |
20,78 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
18,29 |
27,16 |
0,66 |
19,10 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,95 |
14,12 |
0,99 |
4,75 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,15 |
0,10 |
2,60 |
16.08.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
- |
15.08.2024 |
- |
20.06.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-3,98% |
-19,48% |
-28,89% |
-43,11% |
|
|